Elisabeth Parker MSc, PhD

Elisabeth has 20 years’ experience of R&D and commercialization of translational research through licensing and spin-outs. Prior to joining Macrophage Pharma, Elisabeth worked for Cancer Research Technology Ltd (CRT), the development and commercialization arm of Cancer Research UK, and served as a non-executive Director of Arquer Ltd and Azeria Therapeutics Ltd. Prior to joining CRT, Elisabeth was Head of Research at KS Biomedix, the UK quoted Biopharmaceutical company. Elisabeth holds a Ph.D. from the Medical Faculty, Lund University, Sweden.